Key result
Intramyocardial delivery of PDGF with peptide nanofibers reduced infarcted myocardial volume (12.0% vs 34.0% in MI controls; P<0.001) and improved ventricular function without pulmonary toxicity.
Why the study?
Does intramyocardial delivery of PDGF-BB with self-assembling peptide nanofibers improve ventricular function without pulmonary toxicity in rats post-myocardial infarction?
RCT (n=127)
blinded
randomized
Does intramyocardial delivery of PDGF-BB with self-assembling peptide nanofibers improve ventricular function without pulmonary toxicity in rats post-myocardial infarction?
Absolute Event Rate: 12% vs 34%
p-value: p=<0.001
Local intramyocardial delivery of PDGF-BB via self-assembling peptide nanofibers improves long-term cardiac performance and reduces infarct size in a rat model of MI without causing pulmonary toxicity.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for targeted PDGF delivery post-MI; prospective human trials needed before clinical adoption.
Hsieh et al. (2006) conducted an RCT in myocardial infarction (n=127). Platelet-derived growth factor (PDGF)-BB with self-assembling peptide nanofibers (NFs) vs. MI alone or MI+NF was evaluated on Infarcted myocardial volume (p=<0.001). Intramyocardial delivery of PDGF with peptide nanofibers reduced infarcted myocardial volume (12.0% vs 34.0% in MI controls; P<0.001) and improved ventricular function without pulmonary toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: